Form 4: Regulus Therapeutics Director, Hugh Rosen, Acquires Stock Options

Director Hugh Rosen acquired 30,000 stock options in Regulus Therapeutics Inc. on May 16, 2024, as part of the company's Non-Employee Director's Compensation policy.

Summary

• On May 16, 2024, Hugh Rosen, a director of Regulus Therapeutics Inc., was granted 30,000 stock options.
• The options have an exercise price of $2.01.
• These options were granted automatically on the date of the company's Annual Meeting of Stockholders, pursuant to the company's Non-Employee Director's Compensation policy.
• The options will vest ratably over the following twelve months, becoming fully vested one year after the grant date or on the date of the company's next annual stockholder meeting, whichever occurs first, contingent upon continuous service.
• The options expire on May 15, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants to a director, which is a common practice. There's nothing inherently positive or negative about the information itself.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the stock option grant suggests an ongoing commitment to incentivizing directors.

Industry Context

Stock option grants are a common practice in the biotechnology industry to attract and retain qualified directors and align their interests with those of the shareholders. This is a standard compensation practice.

Comparison to Industry Standards

• Stock option grants to non-employee directors are a common practice in the biotech industry.
• The vesting schedule of twelve months is fairly standard.
• The exercise price of $2.01 would need to be compared to the current market price of RGLS to determine if it is at, above, or below market value, which is a key factor in assessing the grant's attractiveness.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially leading to decisions that benefit the company's long-term value.
• The grant has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates